title: Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.
abstract: The most prevalent malignant ovarian neoplasms are epithelial ovarian cancers which is the most common cause of death among all gynecologic malignancies and a result of complex interaction of multiple oncogenes and tumor suppressor genes. The aim of this study was to evaluate expression of survivin and cycline D1 biomarkers in mucinous ovarian neoplasms and their correlations with clinicopathological variables in mucinous ovarian cancers. We analyzed pathological specimens of 98 patients with benign (n = 34), borderline (n = 22) and malignant (n = 42) mucinous ovarian neoplasms. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens. Immunohistochemical analysis revealed that survivin and cyclin D1 expressions were located primarily in the nucleus of ovarian tumor cells and relatively weaker cytoplasmic staining. Survivin expression was significantly higher in malignant tumors (88.1 %) than those found in borderline (18.2 %) and benign tumors (8.8 %) (p < 0.001). Similarly, higher cyclin D1 expression was observed in malignant tumors (100 %) compared to borderline (36.4 %) and benign tumors (5.9 %) (p < 0.001). Expression of all biomarkers analyzed significantly and gradually increased from benign to borderline and borderline to malignant mucinous tumors. In terms of clinicopathological variables, tumor grade, FIGO stage and lymph node methastasis were associated with the expression of both biomarkers. Whereas age exhibited no different correlations in mucinous ovarian cancers. The expressions of survivin and cycline D1 are positively correlated with the malignant potential of mucinous ovarian neoplasms.
authors.affiliation: Department of Histology and Embryology, Faculty of Medicine, Istanbul Medeniyet University, 34710, Istanbul, Turkey. mkanter65@yahoo.com.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Kanter
authors.affiliation: Department of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
authors.forename: Gulay
authors.initials: G
authors.lastname: Turan
authors.affiliation: Goztepe Education and Research Hospital, Clinics of Gynecology and Obstetrics, Istanbul Medeniyet University, Istanbul, Turkey.
authors.forename: Ceyda
authors.initials: C
authors.lastname: Usta
authors.affiliation: Goztepe Education and Research Hospital, Clinics of Gynecology and Obstetrics, Istanbul Medeniyet University, Istanbul, Turkey.
authors.forename: Akin
authors.initials: A
authors.lastname: Usta
authors.affiliation: Department of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
authors.forename: H Hasan
authors.initials: HH
authors.lastname: Esen
authors.affiliation: Department of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
authors.forename: Lema
authors.initials: L
authors.lastname: Tavlı
authors.affiliation: Departments of Gynecology and Obstetrics, Faculty of Medicine, Selcuk University, Konya, Turkey.
authors.forename: Cetin
authors.initials: C
authors.lastname: Celik
authors.affiliation: Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Demirkol
authors.affiliation: Faculty of Medicine, Medical University, Sofia, Bulgaria.
authors.forename: Betül
authors.initials: B
authors.lastname: Kanter
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002467:Cell Nucleus / Q000378:metabolism / Q000473:pathology; D019938:Cyclin D1 / Q000378:metabolism*; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008875:Middle Aged; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000378:metabolism / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology*; D000077022:Survivin; D055815:Young Adult
chemical_list: C107489:BIRC5 protein, human; C530104:CCND1 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D019938:Cyclin D1
keywords: Cycline D1; Immunohistochemical analysis; Mucinous; Ovarian neoplasms; Survivin
references.citation: Curr Opin Cell Biol. 2006 Dec;18(6):609-15
references.pmid: 16934447
references.citation: J Mol Histol. 2014 Dec;45(6):679-87
references.pmid: 25106503
references.citation: Int J Gynecol Cancer. 2011 Oct;21(7):1166-71
references.pmid: 21892090
references.citation: Cancer. 2007 Jan 15;109(2):228-38
references.pmid: 17167759
references.citation: Int J Mol Med. 2002 Aug;10(2):211-6
references.pmid: 12119561
references.citation: Mol Cancer. 2007 Apr 02;6:24
references.pmid: 17407548
references.citation: Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):126-32
references.pmid: 20724919
references.citation: Genes Dev. 1993 Mar;7(3):331-42
references.pmid: 8449399
references.citation: Cancer Lett. 2002 Oct 8;184(1):105-16
references.pmid: 12104054
references.citation: Br J Cancer. 2005 Jan 31;92(2):271-7
references.pmid: 15655541
references.citation: Oncology. 2004;66(4):310-5
references.pmid: 15218299
references.citation: Genes Dev. 1999 Feb 1;13(3):239-52
references.pmid: 9990849
references.citation: Mod Pathol. 2003 Jun;16(6):574-83
references.pmid: 12808063
references.citation: Cell Mol Life Sci. 2002 Aug;59(8):1406-12
references.pmid: 12363043
references.citation: Int J Mol Sci. 2010 Oct 19;11(10):3999-4013
references.pmid: 21152316
references.citation: Anticancer Res. 2007 Jul-Aug;27(4C):2803-8
references.pmid: 17695451
references.citation: Nature. 1998 Dec 10;396(6711):580-4
references.pmid: 9859993
references.citation: Cancer Res. 2014 Jan 15;74(2):420-5
references.pmid: 24408924
references.citation: Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S1-257
references.pmid: 17161154
references.citation: Cancer Sci. 2008 Sep;99(9):1709-14
references.pmid: 18537980
references.citation: Gynecol Oncol. 1999 May;73(2):202-9
references.pmid: 10329035
references.citation: Arch Gynecol Obstet. 2014 Feb;289(2):393-8
references.pmid: 23974278
references.citation: Int J Cancer. 2009 Dec 1;125(11):2631-42
references.pmid: 19672860
references.citation: J Ovarian Res. 2011 Nov 10;4(1):20
references.pmid: 22075440
references.citation: Int J Gynecol Cancer. 2013 Feb;23(2):256-63
references.pmid: 23358177
references.citation: Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):40-3
references.pmid: 15163018
references.citation: Cancer. 2000 Nov 15;89(10):2068-75
references.pmid: 11066047
references.citation: Gynecol Oncol. 1997 Feb;64(2):189-95
references.pmid: 9038263
references.citation: J Pathol. 2007 Mar;211(4):439-46
references.pmid: 17253597
references.citation: Int J Oncol. 2002 Aug;21(2):315-20
references.pmid: 12118327
references.citation: Clin Transl Oncol. 2010 Dec;12(12):783-7
references.pmid: 21156408
references.citation: Int J Oncol. 2001 Sep;19(3):537-42
references.pmid: 11494033
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):6075-86
references.pmid: 16115953
references.citation: Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1095-103
references.pmid: 20231071
references.citation: APMIS. 2009 Mar;117(3):162-75
references.pmid: 19245589
references.citation: Int Rev Cytol. 2005;247:35-88
references.pmid: 16344111